Although the CCR9-CCL25 axis has been proposed as a drug target in the treatment of IBD, the CCR9 antagonist Vercirnon, which showed encouraging results in early phase clinical trials, failed to meet the primary endpoint in a subsequent phase 3 trial [29]. This evidence concerns the gene CCL25 and inflammatory bowel disease.